Drug Approval | March 02, 2022
Amneal enters U.S. biosimilars market with approval of Releukotm
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
New inhalers would have near-zero Global Warming Potential propellant
Subscribe To Our Newsletter & Stay Updated
